Sanofi-aventis (SNY) and Regeneron (REGN) Announce Results from Phase 2 Study with Aflibercept (VEGF Trap) in Advanced Ovarian Cancer Patients
More News related to REGN
- Regeneron Reports Third Quarter 2009 Financial and Operating Results
- RBC Downgrades Regeneron Pharmaceuticals (REGN) to Sector Perform
- Regeneron's Rilonacept Granted European Marketing Authorization for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
- Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
- Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview
More News related to SNY
- Teva Pharmaceutical (TEVA) Announces Commercial Launch of Generic Allegra-D
- Sanofi Pasteur Presents Safety Data on Menactra(R) Vaccine Given to Infants at Infectious Disease Society Meeting
- Crucell NV (CRXL) Up On Renewed Takeover Chatter
- Sanofi-aventis Delivers a Solid Performance in Third Quarter 2009
- Sanofi-aventis Video Q&A: CEO Chris Viehbacher Comments on Q3 '09 Earning and Outlook
More News related to FDA
- Deutsche Bank Initiates Coverage on Wynn Macau with a Buy
- Consensus Forms That Despite Tremendous YTD Move, Ford (F) Is Still Undervalued
- Bernstein Initiates Coverage on Alexion Pharmaceuticals (ALXN) with at Market Perform
- Rodman & Renshaw Initiates Coverage on Silvercorp Metals (SVM) with an Outperform
- Rodman and Renshaw Initiates Coverage on Biosante Pharmaceuticals (BPAX) with an Outperform
Sanofi-aventis (NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced that advanced ovarian cancer patients with recurrent symptomatic malignant ascites (SMA) receiving aflibercept (VEGF Trap) in a randomized, placebo-controlled Phase 2 study experienced a statistically significant improvement in the primary study endpoint, mean time to first repeat paracentesis (removal of fluid from the abdominal cavity), versus placebo control. Symptomatic malignant ascites is an abnormal build-up of fluid in the abdominal cavity in patients with advanced cancer.
Subscribe to EasyStockAlerts.com & Get real-time e-mail alerts when news hits your stocks!
Related Categories
FDAStocks Mentioned
-0.09
+1.18Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
